DE60139398D1 - Mutation, welche mit epilepsie assoziiert ist - Google Patents

Mutation, welche mit epilepsie assoziiert ist

Info

Publication number
DE60139398D1
DE60139398D1 DE60139398T DE60139398T DE60139398D1 DE 60139398 D1 DE60139398 D1 DE 60139398D1 DE 60139398 T DE60139398 T DE 60139398T DE 60139398 T DE60139398 T DE 60139398T DE 60139398 D1 DE60139398 D1 DE 60139398D1
Authority
DE
Germany
Prior art keywords
gaba
receptor
mutant
subunits
acid type
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60139398T
Other languages
German (de)
English (en)
Inventor
Robyn Heather Wallace
John Charles Mulley
Samuel Frank Berkovic
Louise Anne Harkin
Leanne Michelle Dibbens
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bionomics Ltd
Original Assignee
Bionomics Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AUPQ8260A external-priority patent/AUPQ826000A0/en
Priority claimed from AUPR0098A external-priority patent/AUPR009800A0/en
Priority claimed from AUPR4953A external-priority patent/AUPR495301A0/en
Application filed by Bionomics Ltd filed Critical Bionomics Ltd
Application granted granted Critical
Publication of DE60139398D1 publication Critical patent/DE60139398D1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70571—Receptors; Cell surface antigens; Cell surface determinants for neuromediators, e.g. serotonin receptor, dopamine receptor
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/286—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against neuromediator receptors, e.g. serotonin receptor, dopamine receptor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/2857—Seizure disorders; Epilepsy

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Neurology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Analytical Chemistry (AREA)
  • Biophysics (AREA)
  • Hematology (AREA)
  • Biotechnology (AREA)
  • Urology & Nephrology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Wood Science & Technology (AREA)
  • Cell Biology (AREA)
  • Pathology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • General Physics & Mathematics (AREA)
  • General Engineering & Computer Science (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
DE60139398T 2000-06-20 2001-06-20 Mutation, welche mit epilepsie assoziiert ist Expired - Lifetime DE60139398D1 (de)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
AUPQ8260A AUPQ826000A0 (en) 2000-06-20 2000-06-20 New epilepsy gene
AUPR0098A AUPR009800A0 (en) 2000-09-13 2000-09-13 New epilepsy gene
AUPR4953A AUPR495301A0 (en) 2001-05-11 2001-05-11 Novel mutation
PCT/AU2001/000729 WO2001098486A1 (en) 2000-06-20 2001-06-20 Mutation associated with epilepsy

Publications (1)

Publication Number Publication Date
DE60139398D1 true DE60139398D1 (de) 2009-09-10

Family

ID=27158225

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60139398T Expired - Lifetime DE60139398D1 (de) 2000-06-20 2001-06-20 Mutation, welche mit epilepsie assoziiert ist

Country Status (8)

Country Link
US (2) US7157569B2 (enExample)
EP (3) EP1767638A3 (enExample)
JP (1) JP2004500126A (enExample)
AT (1) ATE437948T1 (enExample)
CA (1) CA2411756A1 (enExample)
DE (1) DE60139398D1 (enExample)
NZ (1) NZ522888A (enExample)
WO (1) WO2001098486A1 (enExample)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002079380A2 (en) * 2001-03-29 2002-10-10 Deltagen, Inc. Disruptions in gaba receptor rh02 subunit, methods adn uses thereof
NZ530258A (en) 2001-07-18 2006-01-27 Bionomics Ltd Mutations in SCN1A SCN2A SCN3A SCN8A sodium ion channels and their use in diagnosing epilepsy
AU2003904154A0 (en) 2003-08-07 2003-08-21 Bionomics Limited Mutations in ion channels
AU2003901425A0 (en) 2003-03-27 2003-04-10 Bionomics Limited A diagnostic method for epilepsy
US20090156565A1 (en) * 2004-12-03 2009-06-18 The Children's Hospital Of Philadelphia Composition and use thereof in enhancing a therapeutic effect of an antiepileptic drug
JP2011188837A (ja) * 2010-03-16 2011-09-29 Hirosaki Univ リーシークエンスｄｎａチップおよび最適抗てんかん薬決定方法
RU2639120C2 (ru) * 2011-08-26 2017-12-19 Биал-Портела Энд Ка, С.А. Лечение с использованием ацетата эсликарбазепина или эсликарбазепина
GB201409234D0 (en) * 2014-05-23 2014-07-09 Isis Innovation Method
EP3355938B1 (en) * 2015-10-01 2024-02-07 Goleini Inc. Targeted expression of chloride channels and methods of use thereof
US20200000752A1 (en) * 2016-08-03 2020-01-02 Vanderbilt University Method for Treating Epilepsy
US11470828B2 (en) * 2019-01-17 2022-10-18 Regeneran Pharmaceuticals, Inc. Rodent model of mood disorders

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5654172A (en) * 1995-06-02 1997-08-05 Human Genome Sciences, Inc. Gabaa receptor epsilon subunit

Also Published As

Publication number Publication date
EP1767638A2 (en) 2007-03-28
EP1292676A4 (en) 2004-11-24
US7157569B2 (en) 2007-01-02
JP2004500126A (ja) 2004-01-08
EP1767638A3 (en) 2007-04-11
EP1292676B1 (en) 2009-07-29
EP1292676A1 (en) 2003-03-19
EP1767637A1 (en) 2007-03-28
US20040038236A1 (en) 2004-02-26
NZ522888A (en) 2005-01-28
US20060088913A1 (en) 2006-04-27
CA2411756A1 (en) 2001-12-27
ATE437948T1 (de) 2009-08-15
WO2001098486A1 (en) 2001-12-27

Similar Documents

Publication Publication Date Title
CY1113145T1 (el) Μορια υποδοχεα θυμικης στρωματικης λεμφοποιητινης και χρησεις αυτων
DE60139398D1 (de) Mutation, welche mit epilepsie assoziiert ist
DE69937419D1 (de) Neisseria Meningitidis Antigene und Zusammenstellungen
WO2004053059A3 (en) Mitoneet polypeptide from mitochondrial membranes, modulators thereof, and methods of using the same
ATE532860T1 (de) B7-ähnliche moleküle und deren anwendungen
BR0308946A (pt) Gene que codifica a acetolactato sintase
IL153052A0 (en) Nrg-2 nucleic acid molecules, polypeptides, and diagnostic and therapeutic methods
ATE394484T1 (de) Smad 6 und dessen anwendungen
ATE382685T1 (de) Bakteriophagen-lysin
DK0445971T3 (da) DNA, som koder for et hoved-mideallergen, og anvendelse heraf
WO2001068705A3 (en) Il-17 receptor like molecules and uses thereof
WO2005021029A3 (en) Preventive cancer vaccine based on brother of regulator of imprinted sites molecule (boris)
ATE385517T1 (de) Interferon ähnliche moleküle, und deren verwendungen
BR0011469A (pt) Gm-csf equina
ATE490979T1 (de) Neueskollagen-ähnliches protein clac, dessen vorläufer und dafür kodierende gene
DK0923644T3 (da) G-koblet receptor, der udviser selektiv selektivitet for ATP
WO2002097046A3 (en) B7 related protein-2 molecules and uses thereof
WO2002083736A3 (en) G-protein coupled receptor molecules and uses thereof
WO2003079968A3 (en) Use of an organ-specific self-pathogen for treatment of a non-autoimmune disease of said organ
EP0816498A3 (en) Excitatory amino acid receptor protein and related nucleic acid compounds
WO2003012103A3 (fr) Acides nucleiques codant de nouvelles proteines a boite f, leurs utilisations en diagnostic et en therapie
DE60321443D1 (de) Screening-verfahren für eine prophylaktische und therapeutische Substanz für eine Nierenerkrankung
WO2002083847A3 (en) Cdna encoding the human alpha2 delta4 calcium channel subunit
BR0014444A (pt) Gene prv-1 e uso do mesmo
BR0211038A (pt) Processo de hemihidrogenação de uma dinitrila em aminonitrila correspondente

Legal Events

Date Code Title Description
8364 No opposition during term of opposition